Werner helicase inhibitor RO7589831 produces partial responses in 7 of 66 MSI patients
RO7589831, a Werner syndrome helicase inhibitor, was given to 88 patients with advanced microsatellite instability solid tumors in a phase 1 trial reported in Nature Medicine. Seven of 66 efficacy-evaluable patients had confirmed partial responses, and the median response lasted 10.2+ months. Disease control rate was 74.2 percent. The trial did not identify a maximum tolerated dose. Three of 88 patients stopped treatment because of adverse events.
Patients with advanced mismatch repair-deficient cancers could gain a targeted option if later trials confirm the antitumor activity.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].